Roche has announced that Matt Sause, currently head of Roche Diagnostics’ North America Region, will become CEO of Roche Diagnostics and a member of the Corporate Executive Committee effective January 1, 2023.
“Matt Sause has had an exceptional career with Roche and I am very pleased that we can once again internally appoint a leader of his caliber to become the next CEO Roche Diagnostics,” says Severin Schwan, currently Roche CEO, who has been proposed by the Roche Board of Directors as the new chairman of Roche at the Annual General Meeting on March 14 2023.
Sause began his career with Roche in the United States in 2002 as a senior molecular account manager and progressed in various commercial general management and global product leadership roles spanning both the Diagnostics and Pharma divisions in multiple countries, including Japan, Ireland, Peru, and South Korea. In 2018, he moved to Genentech in the United States to become Lifecycle Leader for Tecentriq Lung and Head and Neck Cancers before eventually taking over his current role as president and CEO for Roche. Cause holds a Bachelor’s degree in microbiology from Miami University in Ohio and an MBA from the University of California, San Diego.
“Matt Sause’s career at Roche has spanned twenty years in multiple countries across Asia, Latin America, Europe and North America in both the Diagnostics and Pharma divisions,” says Thomas Schinecker, the incumbent CEO of the Diagnostics Division and new Roche CEO as of March 15, 2023. “His combination of scientific knowledge with commercial experience makes him an excellent leader for the Diagnostics division.”
